Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

36.52
0.0000
Volume:10
Turnover:365.43
Market Cap:19.17M
PE:- -
High:36.52
Open:36.52
Low:36.52
Close:36.52
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.02
T/O Rate:0.00%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Japan Health Ministry Approves Merck’s Keytruda QLEX for Subcutaneous Use Across Keytruda Indications

Reuters
·
Sep 21

Merck’s Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Approved in Japan for Subcutaneous Administration for All Keytruda® (Pembrolizumab) Indications Approved in Japan

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Ultragenyx price target raised to $35 from $32 at Barclays

TIPRANKS
·
Sep 21

China-Singapore Suzhou Industrial Park Invests Up to RMB 20 Million in Medical Device and Biotech Fund

Stock News
·
Sep 21

Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Stock News
·
Sep 21

Innovative Drug Sector Heats Up: Spotlight on Pure-Play R&D Developers

Deep News
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

TIPRANKS
·
Sep 20

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

GlobeNewswire
·
Sep 20

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Generate Steady Cash

TIPRANKS
·
Sep 19

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

TIPRANKS
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19

Eli Lilly - Inluriyo with Verzenio NOW Available in the United States

THOMSON REUTERS
·
Sep 19